{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:04:32Z","timestamp":1793898272138,"version":"4.8.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ard.2025.01.044","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T07:23:44Z","timestamp":1740641024000},"page":"1001-1010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Responsiveness of systemic lupus erythematosus subjects to iberdomide based on molecular endotypes"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7304-1987","authenticated-orcid":false,"given":"Prathyusha","family":"Bachali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0301-2811","authenticated-orcid":false,"given":"Andrea","family":"Daamen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimon","family":"Korish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8149-5636","authenticated-orcid":false,"given":"Yanhua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrie","family":"Grammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9287-1676","authenticated-orcid":false,"given":"Peter E.","family":"Lipsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2025.01.044_bib0001","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update on the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.01.044_bib0002","doi-asserted-by":"crossref","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ard.2025.01.044_bib0003","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/BOR.0000000000000833","article-title":"Transcriptomics data: pointing the way to subclassification and personalized medicine in systemic lupus erythematosus","volume":"33","author":"Hubbard","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.ard.2025.01.044_bib0004","article-title":"Current status of the evaluation and management of lupus subjects and future prospects","volume":"8","author":"Yavuz","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ard.2025.01.044_bib0005","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000700","article-title":"Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study","volume":"9","author":"Schlencker","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ard.2025.01.044_bib0006","article-title":"01 When and how to escalate therapy in an impending flare","volume":"6","author":"Hahn","year":"2019","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ard.2025.01.044_bib0007","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000303","article-title":"10 most important contemporary challenges in the management of SLE","volume":"6","author":"Felten","year":"2019","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ard.2025.01.044_bib0008","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13073-023-01237-9","article-title":"Analysis of transcriptomic features reveals molecular endotypes of SLE with clinical implications","volume":"15","author":"Hubbard","year":"2023","journal-title":"Genome Med"},{"key":"10.1016\/j.ard.2025.01.044_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000581","article-title":"Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study","volume":"9","author":"Furie","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ard.2025.01.044_bib0010","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1056\/NEJMoa2106535","article-title":"Phase 2 trial of iberdomide in systemic lupus erythematosus","volume":"386","author":"Merrill","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.01.044_bib0011","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/annrheumdis-2022-222212","article-title":"Biological impact of iberdomide in patients with active systemic lupus erythematosus","volume":"81","author":"Lipsky","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.01.044_bib0012","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1023\/A:1015372322419","article-title":"Aiolos and Ikaros: regulators of lymphocyte development, homeostasis and lymphoproliferation","volume":"7","author":"Schmitt","year":"2002","journal-title":"Apoptosis"},{"key":"10.1016\/j.ard.2025.01.044_bib0013","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/annrheumdis-2017-212916","article-title":"Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus","volume":"77","author":"Schafer","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.01.044_bib0014","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/art.24698","article-title":"Novel evidence-based systemic lupus erythematosus responder index","volume":"61","author":"Furie","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.01.044_bib0017","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140380","article-title":"Patient ancestry significantly contributes to molecular heterogeneity of systemic lupus erythematosus","volume":"5","author":"Catalina","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.ard.2025.01.044_bib0018","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/annrheumdis-2021-221662","article-title":"Anti-RNP antibodies are associated with the interferon gene signature but not decreased complement levels in SLE","volume":"81","author":"Hubbard","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.01.044_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2017-000247","article-title":"Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus","volume":"5","author":"Kheir","year":"2018","journal-title":"Lupus Sci Med"},{"issue":"6","key":"10.1016\/j.ard.2025.01.044_bib0020","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.38628","article-title":"Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures","volume":"66","author":"Chiche","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.ard.2025.01.044_bib0021","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/art.40653","article-title":"Stratification of systemic lupus erythematosus patients into three groups of disease activity progression according to longitudinal gene expression","volume":"70","author":"Toro-Dom\u00ednguez","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.01.044_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100291","article-title":"Adults with systemic lupus exhibit distinct molecular phenotypes in a cross-sectional study","volume":"20","author":"Guthridge","year":"2020","journal-title":"EclinicalMedicine"},{"key":"10.1016\/j.ard.2025.01.044_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.860726","article-title":"Molecular taxonomy of systemic lupus erythematosus through data-driven patient stratification: molecular endotypes and cluster-tailored drugs","volume":"13","author":"Garantziotis","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ard.2025.01.044_bib0024","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/acr.24474","article-title":"Increasing ancestral diversity in systemic lupus erythematosus clinical studies","volume":"74","author":"Williams","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"10.1016\/j.ard.2025.01.044_bib0025","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41584-023-00948-y","article-title":"Precision medicine in systemic lupus erythematosus","volume":"19","author":"Fasano","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"9-10","key":"10.1016\/j.ard.2025.01.044_bib0026","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.molimm.2011.03.006","article-title":"The Ikaros gene family: transcriptional regulators of hematopoiesis and immunity","volume":"48","author":"John","year":"2011","journal-title":"Mol Immunol"},{"issue":"1","key":"10.1016\/j.ard.2025.01.044_bib0027","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/imr.12936","article-title":"Established and emergent roles for Ikaros transcription factors in lymphoid cell development and function","volume":"300","author":"Read","year":"2021","journal-title":"Immunol Rev"},{"issue":"5","key":"10.1016\/j.ard.2025.01.044_bib0028","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/leu.2017.25","article-title":"Germline IKAROS mutation associated with primary immunodeficiency that progressed to T-cell acute lymphoblastic leukemia","volume":"31","author":"Yoshida","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.ard.2025.01.044_bib0029","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1074\/jbc.M109.038794","article-title":"Ikaros silences T-bet expression and interferon-gamma production during T helper 2 differentiation","volume":"285","author":"Thomas","year":"2010","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.ard.2025.01.044_bib0030","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/ni.2363","article-title":"Aiolos promotes TH17 differentiation by directly silencing IL2 expression [published correction appears in Nat Immunol. 2014;15(1):109]","volume":"13","author":"Quintana","year":"2012","journal-title":"Nat Immunol."},{"issue":"2","key":"10.1016\/j.ard.2025.01.044_bib0031","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/ard-2024-226051","article-title":"Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways","volume":"84","author":"Moysidou","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ard.2025.01.044_bib0032","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1136\/ard-2023-225445","article-title":"Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials","volume":"83","author":"Baker","year":"2024","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725001979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725001979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:11:00Z","timestamp":1774415460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725001979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0003496725001979"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.01.044","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Responsiveness of systemic lupus erythematosus subjects to iberdomide based on molecular endotypes","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.01.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}